Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells

Molecular Cancer

Volumn 11, Issue , 2012, Pages

  Grabinski, Nicole ^a   Ewald, Florian ^a   Hofmann, Bianca T ^a   Staufer, Katharina ^a,b   Schumacher, Udo ^a   Nashan, Björn ^a   Jücker, Manfred ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

AKT; AKT isoform kinase assay; Hepatocellular carcinoma; MK 2206; Proliferation; RAD001

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER PATIENT; CATALYSIS; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DELIVERY SYSTEMS; DRUG SYNERGISM; FEEDBACK, PHYSIOLOGICAL; FEMALE; GENE KNOCKDOWN TECHNIQUES; HEP G2 CELLS; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; ISOENZYMES; LIVER NEOPLASMS; MICE; MICE, SCID; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84869194238     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-11-85     Document Type: Article

References (50)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001, 94:153-156. 10.1002/ijc.1440, 11668491.
2. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009, 27:1485-1491. 10.1200/JCO.2008.20.7753, 2668555, 19224838.
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390. 10.1056/NEJMoa0708857, 18650514.
4. Bhaskar PT, Hay N. The two TORCs and Akt. Dev Cell 2007, 12:487-502. 10.1016/j.devcel.2007.03.020, 17419990.
5. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009, 9:550-562. 10.1038/nrc2664, 19629070.
6. Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, Tovar V, Roayaie S, Minguez B, Sole M, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008, 135:1972-1983. 1983 e1971-1911, 10.1053/j.gastro.2008.08.008, 2678688, 18929564.
7. Chen JS, Wang Q, Fu XH, Huang XH, Chen XL, Cao LQ, Chen LZ, Tan HX, Li W, Bi J, Zhang LJ. Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9. Hepatol Res 2009, 39:177-186. 10.1111/j.1872-034X.2008.00449.x, 19208038.
8. Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 2009, 27:2278-2287. 10.1200/JCO.2008.20.0766, 2738634, 19332717.
9. Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010, 363:1801-1811. 10.1056/NEJMoa1001671, 21047224.
10. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-456. 10.1016/S0140-6736(08)61039-9, 18653228.
11. Zhu AX, Abrams TA, Miksad R, Blaszkowsky LS, Meyerhardt JA, Zheng H, Muzikansky A, Clark JW, Kwak EL, Schrag D, et al. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer 2011, 117:5094-5102. 10.1002/cncr.26165, 3417818, 21538343.
12. Rizell M, Andersson M, Cahlin C, Hafstrom L, Olausson M, Lindner P. Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int J Clin Oncol 2008, 13:66-70. 10.1007/s10147-007-0733-3, 18307022.
13. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006, 66:1500-1508. 10.1158/0008-5472.CAN-05-2925, 3193604, 16452206.
14. Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, Martinelli E, Ramon y Cajal S, Jones S, Vidal L, et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008, 26:1603-1610. 10.1200/JCO.2007.14.5482, 18332469.
15. Shi Y, Yan H, Frost P, Gera J, Lichtenstein A. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther 2005, 4:1533-1540. 10.1158/1535-7163.MCT-05-0068, 16227402.
16. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007, 26:1932-1940. 10.1038/sj.onc.1209990, 17001314.
17. Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, Majumder PK, Baselga J, Rosen N. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011, 19:58-71. 10.1016/j.ccr.2010.10.031, 3025058, 21215704.
18. Toker A, Yoeli-Lerner M. Akt signaling and cancer: surviving but not moving on. Cancer Res 2006, 66:3963-3966. 10.1158/0008-5472.CAN-06-0743, 16618711.
19. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004, 30:193-204. 10.1016/j.ctrv.2003.07.007, 15023437.
20. Brodbeck D, Hill MM, Hemmings BA. Two splice variants of protein kinase B gamma have different regulatory capacity depending on the presence or absence of the regulatory phosphorylation site serine 472 in the carboxyl-terminal hydrophobic domain. J Biol Chem 2001, 276:29550-29558. 10.1074/jbc.M104633200, 11387345.
21. Brodbeck D, Cron P, Hemmings BA. A human protein kinase Bgamma with regulatory phosphorylation sites in the activation loop and in the C-terminal hydrophobic domain. J Biol Chem 1999, 274:9133-9136. 10.1074/jbc.274.14.9133, 10092583.
22. Chen WS, Xu PZ, Gottlob K, Chen ML, Sokol K, Shiyanova T, Roninson I, Weng W, Suzuki R, Tobe K, et al. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev 2001, 15:2203-2208. 10.1101/gad.913901, 312770, 11544177.
23. Cho H, Mu J, Kim JK, Thorvaldsen JL, Chu Q, Crenshaw EB, Kaestner KH, Bartolomei MS, Shulman GI, Birnbaum MJ. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 2001, 292:1728-1731. 10.1126/science.292.5522.1728, 11387480.
24. Grabinski N, Bartkowiak K, Grupp K, Brandt B, Pantel K, Jucker M. Distinct functional roles of Akt isoforms for proliferation, survival, migration and EGF-mediated signalling in lung cancer derived disseminated tumor cells. Cell Signal 2011, 23:1952-1960. 10.1016/j.cellsig.2011.07.003, 21777670.
25. Santi SA, Lee H. Ablation of Akt2 induces autophagy through cell cycle arrest, the downregulation of p70S6K, and the deregulation of mitochondria in MDA-MB231 cells. PLoS One 2011, 6:e14614. 10.1371/journal.pone.0014614, 3031501, 21297943.
26. Endersby R, Zhu X, Hay N, Ellison DW, Baker SJ. Nonredundant functions for Akt isoforms in astrocyte growth and gliomagenesis in an orthotopic transplantation model. Cancer Res 2011, 71:4106-4116. 10.1158/0008-5472.CAN-10-3597, 3118569, 21507933.
27. Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS, Kotani H. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 2010, 9:1956-1967. 10.1158/1535-7163.MCT-09-1012, 20571069.
28. Rosner M, Siegel N, Valli A, Fuchs C, Hengstschlager M. mTOR phosphorylated at S2448 binds to raptor and rictor. Amino Acids 2010, 38:223-228. 10.1007/s00726-008-0230-7, 19145465.
29. Copp J, Manning G, Hunter T. TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Cancer Res 2009, 69:1821-1827. 10.1158/0008-5472.CAN-08-3014, 2652681, 19244117.
30. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006, 22:159-168. 10.1016/j.molcel.2006.03.029, 16603397.
31. Wang X, Yue P, Kim YA, Fu H, Khuri FR, Sun SY. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. Cancer Res 2008, 68:7409-7418. 10.1158/0008-5472.CAN-08-1522, 2562339, 18794129.
32. Liao Y, Hung MC. Physiological regulation of Akt activity and stability. Am J Transl Res 2010, 2:19-42. 2826820, 20182580.
33. Scheid MP, Woodgett JR. Unravelling the activation mechanisms of protein kinase B/Akt. FEBS Lett 2003, 546:108-112. 10.1016/S0014-5793(03)00562-3, 12829245.
34. Awada A, Cardoso F, Fontaine C, Dirix L, De Greve J, Sotiriou C, Steinseifer J, Wouters C, Tanaka C, Zoellner U, et al. The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. Eur J Cancer 2008, 44:84-91. 10.1016/j.ejca.2007.10.003, 18039566.
35. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.
36. Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T, Russo M, Cancelliere C, Zecchin D, Mazzucchelli L, et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 2010, 120:2858-2866. 10.1172/JCI37539, 2912177, 20664172.
37. Reinke A, Chen JC, Aronova S, Powers T. Caffeine targets TOR complex I and provides evidence for a regulatory link between the FRB and kinase domains of Tor1p. J Biol Chem 2006, 281:31616-31626. 10.1074/jbc.M603107200, 16923813.
38. Ohne Y, Takahara T, Hatakeyama R, Matsuzaki T, Noda M, Mizushima N, Maeda T. Isolation of hyperactive mutants of mammalian target of rapamycin. J Biol Chem 2008, 283:31861-31870. 10.1074/jbc.M801546200, 18812319.
39. Hardt M, Chantaravisoot N, Tamanoi F. Activating mutations of TOR (target of rapamycin). Genes to cells: devoted to molecular & cellular mechanisms 2011, 16:141-151.
40. Sato T, Nakashima A, Guo L, Coffman K, Tamanoi F. Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer. Oncogene 2010, 29:2746-2752. 10.1038/onc.2010.28, 2953941, 20190810.
41. Lee JW, Soung YH, Kim SY, Lee HW, Park WS, Nam SW, Kim SH, Lee JY, Yoo NJ, Lee SH. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005, 24:1477-1480. 10.1038/sj.onc.1208304, 15608678.
42. Tanaka Y, Kanai F, Tada M, Asaoka Y, Guleng B, Jazag A, Ohta M, Ikenoue T, Tateishi K, Obi S, et al. Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese patients. Oncogene 2006, 25:2950-2952. 10.1038/sj.onc.1209311, 16331247.
43. Boyault S, Rickman DS, de Reynies A, Balabaud C, Rebouissou S, Jeannot E, Herault A, Saric J, Belghiti J, Franco D, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007, 45:42-52. 10.1002/hep.21467, 17187432.
44. Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A 2005, 102:802-807. 10.1073/pnas.0408864102, 545580, 15647370.
45. Meric-Bernstam F, Akcakanat A, Chen H, Do KA, Sangai T, Adkins F, Gonzalez-Angulo AM, Rashid A, Crosby K, Dong M, et al. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res 2012, 18:1777-1789. 10.1158/1078-0432.CCR-11-2123, 22422409.
46. Gonzalez E, McGraw TE. Insulin-modulated Akt subcellular localization determines Akt isoform-specific signaling. Proc Natl Acad Sci U S A 2009, 106:7004-7009. 10.1073/pnas.0901933106, 2678468, 19372382.
47. Gonzalez E, McGraw TE. The Akt kinases: isoform specificity in metabolism and cancer. Cell Cycle 2009, 8:2502-2508. 10.4161/cc.8.16.9335, 2997486, 19597332.
48. Ursini-Siegel J, Schade B, Cardiff RD, Muller WJ. Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer 2007, 7:389-397. 10.1038/nrc2127, 17446858.
49. Pal SK, Reckamp K, Yu H, Figlin RA. Akt inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs 2010, 19:1355-1366. 10.1517/13543784.2010.520701, 3244346, 20846000.
50. Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, Baird RD, Delgado L, Taylor A, Lupinacci L, et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 2011, 29:4688-4695. 10.1200/JCO.2011.35.5263, 22025163.